M
Mironid
Small molecule therapeutics for hereditary kidney disease
About Mironid
Mironid is a biopharmaceutical company focused on developing drug candidates for degenerative and rare genetic kidney diseases, major inflammatory diseases, and cancer. The company was spun out of the University of Strathclyde and Heriot-Watt University in 2015, building upon the research of Professor Miles Houslay, who has over 30 years of experience in PDE biology. Mironid is headquartered in Glasgow, Scotland.
Read full description
The company's primary focus is on Autosomal Dominant Polycystic Kidney Disease (ADPKD), a hereditary disorder that affects over 12 million people globally and is a leading cause of kidney failure. Mironid's drug development pipeline targets phosphodiesterase 4 (PDE4) enzymes, which are key in cell signaling pathways. By modulating these enzymes, the company aims to correct aberrant signals that drive disease progression. Their lead product candidates, the LoAc® small molecules, are designed to directly target cyclic AMP (cAMP), a cellular signal active in all stages of ADPKD, to reduce the formation and growth of kidney cysts.
Mironid operates on a business model centered on research and development, funded through venture capital and strategic investments. The company secures capital to advance its programs through preclinical and clinical trials with the ultimate goal of commercializing its therapies. Since its inception, Mironid has raised significant funding, including a Series A round that totaled £35 million after an extension. Key investors include Epidarex Capital, Sofinnova Partners, Roche Venture Fund, the Scottish Investment Bank, and the European Investment Fund.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Glasgow, United Kingdom
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 74.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Kidney, Inflammatory Diseases, Chronic Disease, Spinout, Disease
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Mironid.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2026 | $46M | $184M | Sofinnova Partners · Scottish National Investment Bank · BioGeneration Ventures · Epidarex Capital | ↗ |
| SERIES A✓Equity / VC | Sep 2023 | $41M | $162M | Scottish Enterprise Growth Investments · Epidarex Capital · European Investment Fund · University of Strathclyde | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mironid is 270 monthly website visits, down 80.7% over the last three months. Mironid's team declined 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Epidarex Capital
Scottish Enterprise Growth Investments
European Investment Fund
University of Strathclyde
BioGeneration Ventures
Sofinnova Partners
Scottish National Investment Bank
Roche Venture Fund- UEUniversity of Strathclyde Endowment
Other known investors1 additional known investor
Heriot-Watt University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mironid on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mironid’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.